(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.82%) $83.16
(-1.16%) $1.619
(-0.40%) $2 337.80
(1.00%) $27.53
(0.67%) $928.30
(-0.17%) $0.933
(-0.12%) $11.01
(-0.23%) $0.799
(0.00%) $92.17
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.20%
Live Chart Being Loaded With Signals
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults...
Stats | |
---|---|
Dagens volum | 41 555.00 |
Gjennomsnittsvolum | 54 452.00 |
Markedsverdi | 131.23M |
EPS | $0 ( 2024-03-07 ) |
Neste inntjeningsdato | ( $-0.220 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.790 |
ATR14 | $0.0100 (1.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Tasse Daniel | Buy | 17 094 | Ordinary Shares |
2024-02-06 | Ndu Adora | Buy | 1 825 | Ordinary Shares |
2023-11-22 | Mohideen Pharis | Sell | 2 245 | Ordinary Shares |
2023-11-20 | Boucinha Virginie | Buy | 113 000 | Employee Stock Option (right to buy) |
2023-11-20 | Boucinha Virginie | Buy | 19 000 | Ordinary Shares |
INSIDER POWER |
---|
99.85 |
Last 57 transactions |
Buy: 29 162 445 | Sell: 1 080 406 |
DBV Technologies S.A. Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
PLPC | 0.902 |
GPOR | 0.891 |
MCAA | 0.89 |
ENTF | 0.887 |
MLAI | 0.886 |
PPYA | 0.884 |
AHRN | 0.883 |
FRSG | 0.882 |
ACQR | 0.88 |
FTAA | 0.88 |
10 Mest negative korrelasjoner | |
---|---|
INCY | -0.916 |
SRTS | -0.904 |
FARO | -0.897 |
BXRX | -0.896 |
NWL | -0.895 |
CDXS | -0.892 |
NURO | -0.888 |
AYTU | -0.888 |
RCKY | -0.886 |
SBAC | -0.88 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
DBV Technologies S.A. Økonomi
Annual | 2023 |
Omsetning: | $15.73M |
Bruttogevinst: | $20.23M (128.59 %) |
EPS: | $-0.380 |
FY | 2023 |
Omsetning: | $15.73M |
Bruttogevinst: | $20.23M (128.59 %) |
EPS: | $-0.380 |
FY | 2022 |
Omsetning: | $4.80M |
Bruttogevinst: | $-16.53M (-344.46 %) |
EPS: | $-0.620 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.890 |
Financial Reports:
No articles found.
DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.